Preventing diabetes-related morbidity and mortality in the primary care setting

Journal of the National Medical Association

Volumn 94, Issue 7, 2002, Pages 549-560

  Dagogo Jack, Samuel ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN;

DIABETES MELLITUS; ETHNIC GROUP; HUMAN; KINESIOTHERAPY; LIFESTYLE; MORTALITY; PHYSICIAN ATTITUDE; PRIMARY HEALTH CARE; REVIEW; SELF CARE;

DIABETES COMPLICATIONS; DIABETES MELLITUS; ETHNIC GROUPS; EXERCISE THERAPY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIFE STYLE; PHYSICIAN'S ROLE; PRIMARY HEALTH CARE; SELF CARE;

EID: 0036635314     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Löwe LP, Liu K, Greenland P, et al. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. Diabetes Care 1997;20:163-172.
2. American Diabetes Association. Diabetes Facts and Figures. March 2000. Online Edition.
3. Dagogo-Jack S, Santiago JV. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions. Arch Intern Med 1997;157:1802-1817.
4. Centers for Disease Control and Prevention. Chronic diseases and conditions. Online edition. Atlanta, GA. 2000.
5. American Heart Association. Heart and stroke statistical update. Dallas, TX. 1999.
6. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 23;339:229-34.
7. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: 1990-1998. Diabetes Care 2000;23:1278-1283.
8. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 1998;21:296-309.
9. Songer TJ, Ettaro L. Studies on the cost of diabetes. Centers for Disease Control. Atlanta, GA. 1998.
10. Murphy MB, Kitabchi AE. Management of type 2 diabetes. Tennessee Medicine 2000; 93:398-402.
11. United States Census Bureau Statistics, 1998
12. National estimates and general information about diabetes in the United States: Diabetes Fact Sheets, 1997. Atlanta, US Department of Health and Human Services, Centers for Disease Control and Prevention.
13. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999;22:403-408.
14. Gilmer TP, O'Connor PJ, Manning WG, Rush WA. The cost to health plans of poor glycemic control. Diabetes Care 1997;20:1847-1853.
15. National Center for Health Statistics. Health United States 1996-1997 and Injury Chartbook. Hyattsville, MD:1997
16. Tull ES, Roseman JM. Diabetes in African Americans. In: Diabetes In America, 2nd edn, National Diabetes Data Group, NIH, Bethesda, MD, 1995, p. 613-629.
17. Burke JP, Williams K, Gaskill SP, et al. Rapid rise in the incidence of type 2 diabetes from 1987 to 1996. Arch Intern Med 1999;159:1450-1456.
18. Brancati FL, Kao WHL, Folsom AR, Watson RL, Szklo M. Incident type 2 diabetes mellitus in African American and white adults. JAMA 2000;283:2253-2259.
19. Sprick AN, Simoes EJ, McKeage CB, Chang JC. Diabetes-related deaths in Missouri. Missouri Medicine 1998;95: 21-25.
20. Musey VC, Lee JK, Crawford R, et al. Diabetes in urban African-Americans. 1. Cessation of insulin therapy is the major precipitating cause of diabetic ketoacidosis. Diabetes Care 1995; 18:483-489.
21. Harris MI. Racial and ethnic differences in health care access and health outcomes for adults with type 2 diabetes. Diabetes Care 2001;24:454-459.
22. Wisdom K, Fryzek JP, Havstad SL, et al. Comparison of laboratory test frequency and test results between African-Americans and Caucasians with diabetes: opportunity for improvement. Diabetes Care 1997;20:971-977.
23. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:978-986.
24. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117
25. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulfophonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-853.
26. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713.
27. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
28. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002;23 (suppl 1):S1-S147.
29. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.BMJ. 2000;321:405-412.
30. Jencks SF, Guerdon T, Burwen DR, et al. Quality of medical care delivered to medicare beneficiaries. A profile at state and national levels. JAMA 2000;284:1670-1676.
31. Peters AL, Legorreta AP, Ossorio RC, Davidson MB. Quality of outpatient care provided to diabetic patients. Diabetes Care 1996;10:601-606.
32. Wylie-Rosett J, Basch C, Walker EA, et al. Ophthalmic referral rates for patients with diabetes in primary-care clinics located in disadvantaged urban communities. J Diabetes and its Complications 1995;9:49-51.
33. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Quing IGT and Diabetes Study. Diabetes Care 1997;20, 537-544.
34. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343-1350.
35. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ. 1997;314:1512-1515.
36. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
37. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
38. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
39. Lawler FH, Viaviani N. Patient and physician perspectives regarding treatment of diabetes: compliance with practice guidelines. J Fam Pract 1997;44:369-373.
40. Lorenz RA, Bubb J, Davis D, et al. Changing behavior. Practical lessons from the diabetes control and complications trial. Diabetes Care 1996;19:648-652.
41. Boyle PJ, Schwartz NS, Shah SD, Clutter WE, Cryer PE. Plasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and in nondiabetics. N Engl J Med 1988; 318:1487-1492.